Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00202904
Status:
COMPLETED
Last Update Posted:
2022-02-16
First Post:
2005-09-13
Brief Title:
Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease Study P03740
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Multicenter Randomized Parallel Groups Placebo-Controlled Study Comparing the Efficacy Safety and Tolerability of the Daily Co-Administration of Ezetimibe 10 mg or Ezetimibe Placebo to Ongoing Treatment With Atorvastatin 10 mg in Subjects With Primary Hypercholesterolemia and Coronary Heart Disease
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter randomized parallel group placebo controlled study designed to evaluate the efficacy safety and tolerability of ezetimibe added to ongoing atorvastatin therapy compared with ongoing atorvastatin treatment alone This study will involve subjects with primary hypercholesterolemia and coronary heart disease CHD who are currently being treated with atorvastatin and who would benefit from additional reduction in low-density lipoprotein cholesterol LDL-C
Detailed Description:
This multicenter randomized parallel groups placebo-study is designed for subjects with primary hypercholesterolemia plasma LDL-C concentrations between 26 mmolL 100 mgdL to 41 mmolL 160 mgdL and triglyceride concentrations of 399 mmolL 350 mgdL and coronary heart disease who are currently being treated with atorvastatin 10 mg and would benefit from additional reduction in LDL-C
This study will assess whether the daily co-administration of ezetimibe 10 mg to ongoing treatment with atorvastatin 10 mg will be more effective than treatment with atorvastatin 10 mg alone in further reducing LDL-C concentrations and in achieving LDL-C target goal as defined by the ESC or National Cholesterol Education Program NCEP guidelines at the time of database lock
The primary objective is to compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg versus ezetimibe placebo added daily to ongoing treatment with atorvastatin 10 mg in reducing the concentration of LDL-C at endpoint after 6 weeks of treatment
The secondary objective is to compare the efficacy of ezetimibe 10 mg added to ongoing treatment with atorvastatin 10 mg daily versus ezetimibe placebo added to ongoing treatment with atorvastatin 10 mg daily after 6 weeks of treatment with respect to
The percentage of subjects who achieve the target LDL-C goal as defined by the ESC or NCEP guidelines at the time of database lock
Change in the concentrations of total cholesterol HDL-C and triglycerides
Safety and tolerability Approximately 200 subjects will be enrolled into the study to insure that at least 160 subjects complete the study Each site will enroll approximately 20 subjects for a total of approximately 200 subjects
The duration of the study for each subject will be approximately 7 weeks Each subject will be scheduled for 3-4 study visits Visits 1 and 2 are screening visits these visits may be combined At Visit 3 those subjects who meet the enrollment criteria will be randomized to one of two treatment groups ezetimibe 10 mg or ezetimibe placebo to be taken with ongoing open-label atorvastatin 10 mgday Randomization will be stratified based on the LDL-C level at Visit 3 33 mmolL 130 mgdL or 33 mmolL 130 mgdL Subjects will be treated for 6 weeks and then return for a final visit Visit 4
This study will assess whether the daily co-administration of ezetimibe 10 mg to ongoing treatment with atorvastatin 10 mg will be more effective than treatment with atorvastatin 10 mg alone in further reducing LDL-C concentrations and in achieving LDL-C target goal as defined by the ESC or National Cholesterol Education Program NCEP guidelines at the time of database lock
The primary objective is to compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg versus ezetimibe placebo added daily to ongoing treatment with atorvastatin 10 mg in reducing the concentration of LDL-C at endpoint after 6 weeks of treatment
The secondary objective is to compare the efficacy of ezetimibe 10 mg added to ongoing treatment with atorvastatin 10 mg daily versus ezetimibe placebo added to ongoing treatment with atorvastatin 10 mg daily after 6 weeks of treatment with respect to
The percentage of subjects who achieve the target LDL-C goal as defined by the ESC or NCEP guidelines at the time of database lock
Change in the concentrations of total cholesterol HDL-C and triglycerides
Safety and tolerability Approximately 200 subjects will be enrolled into the study to insure that at least 160 subjects complete the study Each site will enroll approximately 20 subjects for a total of approximately 200 subjects
The duration of the study for each subject will be approximately 7 weeks Each subject will be scheduled for 3-4 study visits Visits 1 and 2 are screening visits these visits may be combined At Visit 3 those subjects who meet the enrollment criteria will be randomized to one of two treatment groups ezetimibe 10 mg or ezetimibe placebo to be taken with ongoing open-label atorvastatin 10 mgday Randomization will be stratified based on the LDL-C level at Visit 3 33 mmolL 130 mgdL or 33 mmolL 130 mgdL Subjects will be treated for 6 weeks and then return for a final visit Visit 4
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None